Recently, it has been shown that a deficiency in ChGn-1 (chondroitin N-acetylgalactosaminyltransferase-1) reduced the numbers of CS (chondroitin sulfate) chains, leading to skeletal dysplasias in mice. Although these results indicate that ChGn-1 regulates the number of CS chains, the mechanism mediating this regulation is not clear. ChGn-1 is thought to initiate CS biosynthesis by transferring the first GalNAc (Nacetylgalactosamine) to the tetrasaccharide in the protein linkage region of CS. However, in vitro chondroitin polymerization does not occur on the non-reducing terminal GalNAc-linkage pentasaccharide structure. In the present study we show that several different heteromeric enzyme complexes composed of different combinations of four chondroitin synthase family members synthesized more CS chains when a GalNAc-linkage pentasaccharide structure with a non-reducing terminal 4-O-sulfation was the CS acceptor. In addition, C4ST-2 (chondroitin 4-O-sulfotransferase-2) efficiently transferred sulfate from 3 -phosphoadenosine 5 -phosphosulfate to position 4 of non-reducing terminal GalNAclinkage residues, and the number of CS chains was regulated by the expression levels of C4ST-2 and of ChGn-1. Taken together, the results of the present study indicate that C4ST-2 plays a key role in regulating levels of CS synthesized via ChGn-1.
INTRODUCTION
CSs (chondroitin sulfates) are covalently bound to specific serine residues in the core regions of many proteins through a common carbohydrate-protein linkage tetrasaccharide GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser. Following the complete synthesis of the linkage-region tetrasaccharide, the first GalNAc (Nacetylgalactosamine) residue is transferred to a GlcA (glucuronic acid) residue in the linkage-region tetrasaccharide, triggering the synthesis of CS. Next, GlcA and GalNAc residues are alternately transferred on to growing CS chains, resulting in the formation of the polymer sugar backbone of CS [1] . After the synthesis of the CS sugar backbone on this tetrasaccharide, numerous modifications, including sulfation, occur under tight spatio-temporal regulation producing mature and functional GAG (glycosaminoglycan) chains that exert specific biological functions that are dependent on their specific structures.
To date, six glycosyltransferases involved in the biosynthesis of CS have been cloned. We and others have identified the six chondroitin-synthesizing enzymes: ChSy (chondroitin synthase)-1, ChSy-2, ChSy-3, ChPF (chondroitin-polymerizing factor) and ChGn (chondroitin GalNAc transferase)-1 and -2 [2] [3] [4] [5] [6] [7] [8] [9] . ChSy-1, ChSy-2 and ChSy-3 show dual glycosyltransferase activities, GlcAT-II (GlcA transferase II) and GalNAcT-II (GalNAc transferase II), that are responsible for synthesizing the repeating disaccharide units of CS [2] [3] [4] , and ChGn-1 and -2 catalyse chain initiation and elongation, exhibiting activities of GalNAcT-I and -II [6] [7] [8] [9] . In addition, seven sulfotransferases involved in the sulfation of CS, including four sulfotransferases involved in the sulfation of position 4 of the GalNAc residue, have been cloned [10] . C4STs (chondroitin 4-Osulfotransferases)-1, -2 and -3 are responsible for the sulfation of position 4 of the GalNAc residues in CS, whereas D4ST-1 (dermatan 4-O-sulfotransferase-1) catalyses the transfer of sulfate residues to GalNAc residues located next to IdoUA (iduronic acid) residues in DS (dermatan sulfate) [11] [12] [13] [14] [15] . C6ST-1 (chondroitin 6-O-sulfotransferase-1) transfers sulfate to position 6 of GalNAc residues [16, 17] . The 2-O-sulfation of GlcA and IdoUA is catalysed by uronyl 2-O-sulfotransferase [18] . GalNAc4S-6ST (GalNAc 4-sulfate 6-O-sulfotransferase) transfers a sulfate residue to position 6 of GalNAc(4-O-sulfate) formed by C4ST [19] .
Previously, we demonstrated that chondroitin is polymerized with alternating GalNAc and GlcA residues on the linkageregion tetrasaccharide of α-TM (α-thrombomodulin) when any two of four proteins, ChSy-1, ChSy-2, ChSy-3 and ChPF, were co-expressed [3] [4] [5] . These results indicated that ChGn-1 and ChGn-2, both of which have both GalNAcT-I and -II activity, were dispensable for chondroitin polymerization on the linkageregion tetrasaccharide [3] [4] [5] ; however, recently it was shown that a deficiency in ChGn-1 reduced the number of CS chains, leading to skeletal dysplasias in mice [20] . Taken together, these results indicate that the transfer of a single GalNAc residue to the tetrasaccharide linkage region by ChGn-1 and the activity of chondroitin polymerases comprising any two of the ChSy-1, ChSy-2, ChSy-3 and ChPF proteins are both important for efficient biosynthesis of CS chains.
Given these findings, we hypothesized that the non-reducing terminal GalNAc-linkage structure formed by ChGn-1 would markedly enhance the number of CS chains produced by chondroitin polymerases comprising any two of the ChSy-1, ChSy-2, ChSy-3 and ChPF proteins (Figure 1) . However, the results of the present study demonstrated that a non-reducing terminal GalNAc-linkage structure did not serve as a chondroitin polymerization substrate. In the present paper we report that
Figure 1 Initiation of CS polymerization
CS is synthesized as proteoglycans on specific serine residues in the GAG-protein linkage region, GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser. Following the complete synthesis of the linkage-tetrasaccharide sequence, the transfer of a single GalNAc residue to the tetrasaccharide linkage region by any two of ChSy-1, ChSy-2, ChSy-3 or ChPF (broken line), or by ChGn-1 (solid line) initiates the assembly of CS. Thus it was expected that the non-reducing terminal GalNAc-linkage structure formed by ChGn-1 would markedly enhance the number of CS chains produced by chondroitin polymerases, meaning any two of ChSy-1, ChSy-2, ChSy-3 and ChPF.
a non-reducing terminal GalNAc(4-O-sulfate)-linkage structure on CS resulted in an increase in the number of CS chains that were synthesized by multiple enzyme complexes comprising combinations of four ChSy family members and that C4ST-2 was involved in the mechanism that resulted in an increase in the number of CS chains that was mediated by ChGn-1. 200 10/300 GL columns were purchased from Amersham Pharmacia Biotech. α-TM with a truncated linkage-region tetrasaccharide, GlcAβ1-3Galβ1-3Galβ1-4Xyl, was purified and structurally characterized as described previously [21, 22] .
EXPERIMENTAL

Polymerization assay and identification of polymerization reaction products
First, a GalNAc transfer reaction was conducted; α-TM that contained the linkage-region tetrasaccharide GlcAβ1-3Galβ1-3Galβ1-4Xyl (1 nmol) was used as an acceptor in the incubation mixture, which contained the following constituents in a total volume of 20 μl: 10 μl of the soluble form of ChGn-1-bound beads [6] as the enzyme source, 0.25 mM UDP-GalNAc or UDP- [ 3 H]GalNAc (2×10 5 d.p.m.), 100 mM Mes buffer (pH 5.8) and 10 mM MnCl 2 . Then, the reaction products were separated by gel-filtration chromatography on a Superdex TM peptide column that had been equilibrated and eluted with 0.25 M NH 4 HCO 3 /7 % propan-1-ol. Next, 4-O-sulfation of the GalNAc residue was performed using GalNAc-TM (GalNAcβ1-4GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-TM) (1 nmol) as an acceptor in an incubation mixture, which contained the following constituents in a total volume of 30 μl: 10 μl of the soluble form of C4ST-2-bound beads [15] as the enzyme source, 50 mM imidazole/HCl (pH 6.8), 2 mM dithiothreitol and 10 μM [
35 S]PAPS (3×10 5 d.p.m.). Then, the reaction products were separated by gel-filtration chromatography on a Superdex TM peptide column that had been equilibrated and eluted with 0.25 M NH 4 HCO 3 /7 % propan-1-ol. The fractions containing the enzyme reaction products were pooled and evaporated to dryness. The isolated reaction products were used as substrates for polymerization reactions. Polymerization reactions were simultaneously incubated in parallel in reaction mixtures containing the following constituents in a total volume of 20 μl:
35 S]GalNAc(4S)-TM}, 0.25 mM UDP-GalNAc, 0.25 mM UDP-GlcA, 100 mM Mes buffer (pH 6.5), 10 mM MnCl 2 , and 10 μl of the soluble form of ChSy-1-ChPF-, ChSy-1-ChSy-2-, ChSy-1-ChSy-3-, ChSy-2-ChPF-, ChSy-2-ChSy-3-or ChSy-3-ChPF-bound beads. The mixtures were incubated at 37
• C overnight, and the 3 H-or 35 S-labelled products were then separated by gel-filtration chromatography on a Superdex TM 200 column equilibrated and eluted with 0.25 M NH 4 HCO 3 /7 % propan-1-ol. Fractions (0.4 ml each) were collected at a flow rate of 0.4 ml/min, and radioactivity was measured with a liquid scintillation counter. A cDNA fragment encoding ChGn-1 (HUGO nomenclature CSGALNACT1) was amplified by RT (reverse transcription) using total RNA from G361 human melanoma cells (A.T.C.C. CRL-1424) as a template, and the forward primer 5 -CGGGAT-CCTCTGGACGCATGGCTGATTC-3 and the reverse primer 5 -CGGGATCCCAGCTGGCACTGCCCAGG-3 ; each primer contained a BamHI site. PCR was performed with KOD-Plus DNA polymerase (TOYOBO) for 30 cycles at 94
• C for 30 s, 58
• C for 42 s and 68
• C for 180 s in 5 % (v/v) DMSO. The PCR fragments were subcloned into the BamHI sites of the pCMV expression vector (Invitrogen). The insert of the plasmid constructs (pCMV-ChGn-1) was confirmed by DNA sequencing. The expression plasmid (6.7 μg) was transfected into L and sog9 cells on 100-mm plates using FuGENE ® 6 (Roche Applied Science), according to the manufacturer's protocol. Transfectants were cultured in the presence of 300 μg/ml G418, after which the resistant colonies were picked and propagated for experiments.
ChGn-1 silencing in L cells was performed using MISSION shRNA (short hairpin RNA) (Sigma). Plasmids (6.7 μg) encoding shRNA were transfected into L cells on 100-mm plates using FuGENE ® 6 according to the manufacturer's protocol. Transfectants were cultured in the presence of 0.4 mg/ml puromycin. Resistant colonies were then picked and propagated for experiments.
Quantitative real-time RT-PCR
Total RNA was extracted from L cells or sog9 cells using TRIzol ® reagent (Invitrogen). The cDNA was synthesized from ∼1 μg of total RNA using Moloney murine leukemia virus reverse transcriptase (Promega) and oligo(dT) 20 -M4 adaptor primers (TaKaRa). The primer sequences used were as follows: ChGn-1, forward primer 5 -AGAA-GAAATAAATGAAGTCAAAGGAATAC-3 and reverse primer 5 -GAAGTAGTAGTCCACATCACAG-3 ; ChGn-2, forward primer 5 -CCTAGAATCTGTCACCAGT-3 and reverse primer 5 -GTTAAGGAATTCGGCTGAGAAATA-3 ; C4ST-1, forward primer 5 -ACCTCGTGGGCAAGTATGAG-3 and reverse primer 5 -TCTGGAAGAACTCCGTGGTC-3 ; C4ST-2, forward primer 5 -ATCAGCATCACCAGCAACA-3 and reverse primer 5 -TGTGGCCTGGAGAGAGAC-3 ; and GAPDH (glyceraldehyde-3-phosphate dehydrogenase), forward primer 5 -CATC-TGAGGGCCCACTG-3 and reverse primer 5 -GAGGC-CATGTAGGCCATGA-3 . Quantitative real-time RT-PCR was performed using a FastStart DNA Master plus SYBR Green I kit (Roche Diagnostics) in a LightCycler ST300 (Roche Diagnostics). The expression levels of ChGn-1, ChGn-2, C4ST-1 (HUGO nomenclature CHST11) or C4ST-2 (HUGO nomenclature CHST12) mRNA were normalized to that of the GAPDH transcript.
Derivatization of GAGs from L and sog9 cells using a fluorophore, 2-aminobenzamide
GAGs from L and sog9 cells were prepared as described previously [23] . The purified GAG fraction was digested with chondroitinase ABC, and the digests were then derivatized with 2-aminobenzamide and analysed by HPLC as described previously [24] .
Gel-filtration chromatography of GAGs
To measure the GAG chain lengths, the purified GAG fraction was subjected to reductive β-elimination using NaBH 4 /NaOH, and then analysed by gel-filtration chromatography on a Superdex TM 200 column (10 mm×300 mm) eluted with 0.2 M ammonium bicarbonate at a flow rate of 0.4 ml/min. Fractions were collected at 3-min intervals, freeze-dried and digested with chondroitinase ABC. The digests were derivatized with 2-aminobenzamide, and then analysed by HPLC on an amine-bound PA-03 column, as described previously [24, 25] .
Expression of the soluble forms of the recombinant C4ST-1, C4ST-2 and D4ST-1, and identification of the reaction products
Each expression plasmid (6.0 μg) was transfected into COS-1 cells on 100-mm plates using FuGENE ® 6 according to the manufacturer's protocol and as described previously [15] . At 2 days after transfection, 1 ml of the culture medium was collected and incubated with 10 μl of IgG-Sepharose (Amersham Pharmacia Biotech) for 1 h at 4
• C. The beads recovered by centrifugation (150 g at 4
• C for 5 min) were washed with and then resuspended in the assay buffer [50 mM imidazole/HCl (pH 6.8)], and the washed beads were tested for sulfotransferase activity. The assays used to detect sulfotransferase have been described previously [15] and were used with slight modifications. Briefly, the standard reaction mixture (30 μl) contained 10 μl of resuspended beads, 50 mM imidazole/HCl (pH 6.8), 2 mM dithiothreitol, 10 μM [
35 S]PAPS (3×10 5 d.p.m.) and 1 nmol of GalNAc-TM as an acceptor substrate. The reaction mixtures were incubated at 37
• C overnight and subjected to gel filtration using the Superdex TM peptide column with 0.25 M NH 4 HCO 3 /7 % propan-1-ol as the eluent. The radioactive fractions containing the enzyme reaction products were pooled and evaporated to dryness. The isolated reaction products were subjected to reductive β-elimination using NaBH 4 /NaOH, and then digested with chondroitinase AC-II. The enzymatically digested products were analysed using the Superdex TM peptide column with 0.25 M NH 4 HCO 3 /7 % propan-1-ol as the eluent.
Construction of an expression vector for C4ST-2 and preparation of cells that stably expressed C4ST-2
A cDNA fragment encoding C4ST-2 was amplified using mouse heart Marathon-Ready cDNA (Clontech) as a template by two-round PCR using specific primer sets. The first PCR was performed with the forward primer 5 -CCAGCTGTG-CACAAGGCTGA-3 and the reverse primer 5 -TGCCTG-TCACACCAGGAAGC-3 , followed by nested PCR with the nested forward primer 5 -GCACAAGGCTGAAGTGAAGG-3 and the reverse primer 5 -AAGGAAGCCAGGAGAGAACC-3 . Each PCR was carried out using KOD-Plus in the presence of 5 % (v/v) DMSO and was subjected to 30 cycles at 94
• C for 30 s, 55
• C for 42 s, and 68
• C for 2.5 min. Amplified cDNA fragments of the expected size (∼1.4 kb) were purified and subcloned into pGEM ® -T Easy vectors (Promega). The cDNA encoding a full-length form of C4ST-2 from pGEM ® -T Easy-C4ST-2 vectors was digested with EcoRI and subcloned into the EcoRI site of a pCMV expression vector. The insert of the plasmid constructs (pCMV-C4ST-2) was confirmed by DNA sequencing. The expression plasmid (6.7 μg) was transfected into L or sog9 cells on 100-mm plates using FuGENE ® 6, according to the manufacturer's protocol. Transfectants were cultured in the presence of 300 μg/ml G418, after which the resistant colonies were picked and propagated for experiments.
RESULTS
A GalNAc-linkage structure did not serve as a chondroitin polymerization substrate
Recently, it has been shown that ChGn-1-deficient mice showed a 50% decrease in CS levels in developing cartilage and a delay in cartilage development [20] . These results indicated that the non-reducing terminal GalNAc-linkage structure formed by ChGn-1 could markedly enhance the production of CS chains mediated by chondroitin polymerases that synthesize the CS backbone. Previously, we demonstrated that chondroitin ChSy-2 and ChSy-3 (E), and ChSy-3 and ChPF (F) were used as the enzyme source, as described in the Experimental section.
3 H-Labelled or 35 S-labelled polymerization reaction products were first isolated by gel filtration, subjected to reductive β-elimination using NaBH 4 /NaOH, and then rechromatographed on a Superdex TM 200 column with 0.25 M NH 4 HCO 3 /7 % propan-1-ol as the eluent. Arrowheads numbered 65.5, 37.5 and 18.1 indicate the eluted position of 65.5 kDa saccharides, 37.5 kDa saccharides and 18.1 kDa saccharides respectively, derived from commercial polysaccharides of known sizes (dextran average molecular masses of 200 kDa, 65.5 kDa, 37.5 kDa and 18.1 kDa; all from Sigma). The total volume was a fraction of ∼60 (not shown).
polymerization takes place when any two of four proteins (ChSy-1, ChSy-2, ChSy-3 or ChPF) were co-expressed and the acceptor substrate was α-TM with a truncated linkage-region tetrasaccharide, GlcAβ1-3Galβ1-3Galβ1-4Xyl [3] [4] [5] . Therefore in the present study we measured polymerization activity using α-TM or [ 3 H]GalNAc-TM with the non-reducing terminal GalNAclinkage pentasaccharide structure as an acceptor substrate and co-expression of any two of the ChSy-1, ChSy-2, ChSy-3 and ChPF proteins as the enzyme source (see the Experimental section). Polymerization did not occur with any enzyme subunit combination when [ 3 H]GalNAc-TM was the acceptor substrate ( Figure 2 , open squares). These results indicated that the nonreducing terminal GalNAc-linkage structure did not serve as a chondroitin polymerization substrate.
Involvement of ChGn-1 in increasing the number of CS chains
Previously, we found that overexpression of ChGn-1 slightly increases CS levels in L cells (see Table 2 in [26] ). This result indicates that ChGn-1 might regulate the production of CS. Therefore we examined the effects of shRNA-mediated knockdown of ChGn-1 in L cells in the present study. The efficiency of gene shRNA-mediated silencing was determined by quantitative real-time RT-PCR. Transfection with ChGn-1 shRNA (L-shRNA ChGn-1-1 and L-shRNA ChGn-1-2 cells: two different shRNAs targeted against ChGn-1 were used) resulted in a 60-80 % reduction in steady-state ChGn-1 mRNA and an 18-22 % decrease in CS when compared with control L cells (Table 1 ). These findings indicate that the knockdown of ChGn-1 decreases CS levels in L cells, corresponding to expression levels of ChGn-1 (Table 1) .
We next compared the CS chain lengths in L-shRNA ChGn-1-1, L-shRNA ChGn-1-2, and mock-transfected L cells. Gel-filtration analysis using a Superdex TM 200 column revealed that the length of CS chains in L-shRNA ChGn-1-1-and L-shRNA ChGn-1-2-transfected cells was similar to that in mock-transfected cells (Figure 3 ). Thus both in vitro and in vivo studies have shown that ChGn-1 regulates the number of CS chains, in spite of the fact that chondroitin polymerization did not occur on the non-reducing terminal GalNAc-linkage structure.
Involvement of the GalNAc(4-O-sulfate)-linkage structure in chondroitin polymerization
We recently found that the non-reducing terminal 4-O-sulfation of GalNAc residues on the repeating disaccharide region synthesized by C4ST-1 and ChGn-2 facilitates the elongation of CS chains only by chondroitin polymerase consisting of ChSy-1 and ChPF [26] . On the basis of this result, we predicted that the nonreducing terminal 4-O-sulfation of newly synthesized GalNAclinkage regions might promote the elongation of CS chains by chondroitin polymerases. We measured polymerization activity using [
35 S]GalNAc(4S)-TM as acceptor substrates, and the coexpression of any combination of two ChSy-1, ChSy-2, ChSy-3 and ChPF as the enzyme source. Reaction products obtained were subjected to reductive β-elimination using NaBH 4 /NaOH, and the radiolabelled saccharides released were analysed by gel-filtration chromatography using a Superdex TM 200 column. Chondroitin polymerization was induced on the [
35 S]GalNAc(4S)-TM when any combination of protein subunits was used as the enzyme source ( Figure 2, closed circles) . Notably, the length of the chondroitin chains synthesized on [
35 S]GalNAc(4S)-TM by ChSy-1-ChPF, ChSy-1-ChSy-3 or ChSy-3-ChPF, and on α-TM were comparable (Figures 2A, 2C and 2F ), but the chondroitin chains polymerized on [
35 S]GalNAc(4S)-TM by ChSy-1-ChSy-2, ChSy-2-ChPF or ChSy-2-ChSy-3 were longer than those formed on α-TM ( Figures 2B, 2D and 2E ). These results indicated that chondroitin polymerization was facilitated by the non-reducing terminal GalNAc(4-O-sulfate)-linkage structure. Thus multiple enzyme complexes, which each comprised any two of four ChSy family members, synthesized more CS chains when there was a non-reducing terminal GalNAc(4-O-sulfate)-linkage structure on the CS acceptor substrate.
Identification of sulfotransferases involved in the 4-O-sulfation of the GalNAc-linkage pentasaccharide
Reportedly, C4ST-1, C4ST-2 and D4ST-1 catalyse the transfer of sulfate from PAPS to position 4 of the internal GalNAc residue of chondroitin [14, 15] . However, it is not clear whether C4ST-1, C4ST-2 or D4ST-1 is also responsible for transferring the sulfate to position 4 of the non-reducing terminal GalNAc-linkage residue. Hence, we examined whether C4ST-1, C4ST-2 and/or D4ST-1 could sulfate the GalNAc-linkage residue. For this analysis, the recombinant C4ST-1, C4ST-2 and D4ST-1 were expressed and initially evaluated for sulfotransferase activities towards internal GalNAc residues using polymer 
Table 2 Disaccharide composition of CS in mock-, C4ST-2-and shC4ST-2-transfected L cells
Relative expression of C4ST-2* 1.0 7. chondroitin as an acceptor [15] . The activity of C4ST-1, C4ST-2 or D4ST-1 was 550, 81 or 89 pmol/μg per h respectively. Then, sulfotransferase activity was determined using GalNAc-TM as the acceptor substrate and [
35 S]PAPS as the donor substrate. C4ST-2 transferred sulfate to GalNAc-TM much more efficiently than did C4ST-1 ( Figure 4A ). D4ST-1 showed no activity when GalNAc-TM was used as an acceptor ( Figure 4A , open triangles, inset). To identify the 35 S-labelled products synthesized on the GalNAc-linkage pentasaccharide of α-TM, the products were subjected to reductive β-elimination and then digested to completion with chondroitinase AC-II, which cleaves the β1-4-N-acetylgalactosaminidic linkage. The digests were separated by gel-filtration chromatography using a Superdex TM peptide column, and a large peak was detected at the position corresponding to GalNAc-4-O-SO 4 ( Figure 4B, closed circles) . In sharp contrast, C4ST-1 transferred sulfate to the GalNAc residues and to a Gal residue of the linkage region, albeit transfer to the linkage region was much less efficient ( Figure 4B , open circles, inset). These results indicated that C4ST-2 efficiently and selectively transferred sulfate from PAPS to the non-reducing terminal GalNAc-linkage residue.
Introduction of ChGn-1 to sog9 cells
Previously we found that C4ST-1 regulates the 4-O-sulfation of CS and the length and amount of CS chains [23] , and that, (A) GalNAcβ1-4GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-TM was tested as a potential acceptor for sulfotransferase reactions, where C4ST-1 (᭺), C4ST-2 (᭹) or D4ST-1 ( ) was used as an enzyme source, as described in the Experimental section.
35 S-Labelled sulfotransferase reaction products were first isolated by gel filtration, subjected to reductive β-elimination using NaBH 4 /NaOH, and then rechromatographed on a Superdex TM peptide column with 0.25 M NH 4 HCO 3 /7 % propan-1-ol as the eluent. The inset shows a different scaling when C4ST-1 (᭺) or D4ST-1 ( ) was used as an enzyme source. (B) 35 S-Labelled sulfotransferase reaction products were digested with chondroitinase AC-II. The chondroitinase AC-II digests derived from reaction products using C4ST-1 (᭺) or C4ST-2 (᭹) were isolated by gel filtration on a Superdex TM peptide column using 0.25 M NH 4 HCO 3 /7 % propan-1-ol as the eluent. The inset shows a different scaling when C4ST-1 (᭺) was used as an enzyme source. The arrowhead indicates the elution position of GalNAc-4-SO 4 . The peaks marked by an asterisk indicate the elution position of GlcAβ-Gal(4-O-sulfate)-Gal-Xyl-ol. Purified CS fractions were subjected to reductive β-elimination using NaBH 4 /NaOH and then analysed by gel-filtration chromatography on a Superdex TM 200 column (10 mm×300 mm). The digests of individual fractions obtained with chondroitinase ABC were derivatized with 2-aminobenzamide and then analysed by HPLC. The amounts of the 2-aminobenzamide derivatives of unsaturated disaccharides were calculated based on fluorescence intensity. Samples from sog9-ChGn-1-1 () and mock-transfected sog9 (ᮀ) cells are shown. Arrowheads indicate the size of molecular mass standards in kDa. Data represent one of a series of three independent experiments, and all three experiments gave essentially the same results.
however, overexpression of ChGn-1 increases CS levels in C4ST-1-deficient sog9 cells (see sog9-ChGn-1-1 and sog9-ChGn-1-2 cells in Table 3 in [26] ). To further assess whether C4ST-1 was dispensable for regulating the number of CS chains synthesized by ChGn-1, the lengths of CS chains in sog9-ChGn-1-1-transfected and mock-transfected sog9 cells were compared. Gel-filtration analysis using a Superdex TM 200 column revealed that the length of CS chains in sog9-ChGn-1-1 cells was similar to that in mocktransfected cells ( Figure 5 ). These results indicated that ChGn-1 regulated the number of CS chains without C4ST-1, and that C4ST-2 might play a key role in controlling the number of CS moieties synthesized by ChGn-1.
Introduction of C4ST-2 into L cells
We next examined whether C4ST-2 regulates the number of CS chains by preparing L cells in which C4ST-2 is overexpressed. The amount and disaccharide composition of CS isolated from two stable L cell clones that express different levels of C4ST-2 (high expression L-C4ST-2-1 and low expression L-C4ST-2-2 cells) were analysed by HPLC (Table 2) . Although the disaccharide compositions of CS found in L-C4ST-2-1 and L-C4ST-2-2 cells were similar to those in control L cells, the levels of CS were higher in L-C4ST-2-1 and L-C4ST-2-2 cells; moreover, the CS levels corresponded to the C4ST-2 expression levels ( Table 2) .
We then determined whether knockdown of C4ST-2 decreased the amount of CS in L cells. The efficiency of gene silencing was determined by quantitative RT-PCR. Transfection with C4ST-2 shRNA (L-shRNA C4ST-2-1 or L-shRNA C4ST-2-2 cells: two different shRNAs targeted against C4ST-2 were used) resulted in a 70-80 % knockdown of C4ST-2 mRNA and a 33-47 % decrease in the amount of CS when compared with control L cells. These results indicated that C4ST-2 regulated CS levels, and that CS levels were proportional to C4ST-2 expression levels ( Table 2) .
Involvement of C4ST-2 in the increased number of CS chains
We next compared the lengths of CS chains in L-C4ST-2-1-, L-C4ST-2-2-, L-shRNA C4ST-2-1-, L-shRNA C4ST-2-2-and mock-transfected L cells. Gel-filtration analysis using a 
DISCUSSION
Previously, we have demonstrated that co-expression of any two of four ChSy family members, ChSy-1, ChSy-2, ChSy-3 and ChPF, promoted chondroitin polymerization with alternating GalNAc and GlcA residues on the linkage-region tetrasaccharide of α-TM [3] [4] [5] . These results indicated that ChGn-1 and ChGn-2, both of which have GalNAcT activity, were not required for chondroitin polymerization on the linkage-region tetrasaccharide. In fact, our recent studies found that knockdown of ChGn-2 resulted in a decrease in CS chain length and that ChGn-2 was involved in CS chain elongation [26] . In contrast with ChGn-2, ChGn-1-deficient mice had fewer CS chains in developing cartilage and a delayed cartilage development [20] . These results suggest that ChGn-1 is required for efficient initiation of CS chain polymerization; moreover, the presence of chondroitin polymerase, meaning any two of ChSy-1, ChSy-2, ChSy-3 and ChPF, does not compensate for the loss of ChGn-1. In addition, the number of CS chains on specific core proteins may be tightly regulated during cartilage development by temporal and spatial regulation of ChGn-1 expression, and progression of cartilage disease may result from defects in these regulatory systems.
Sakai et al. [27] reported that in vitro overexpression of ChGn-1 in chondrosarcoma cells increased the number of CS chains. Their observations, like ours, indicate that ChGn-1 regulates the initiation of CS. Nevertheless, the results of the present study indicated that chondroitin polymerization did not occur on the non-reducing terminal GalNAc-linkage structure (Figure 2, open  squares) . Interestingly, the non-reducing terminal GalNAc(4-Osulfate)-linkage structure of CS was associated with an increased number of CS chains when the enzyme source was any one of several complexes that comprised any two of the four ChSy family (Figure 2 ). In addition, C4ST-2 efficiently transferred sulfate to the non-reducing terminal GalNAc-linkage residue (Figure 4 ). In conjunction with our previous findings, these results indicate that ChGn-1 co-operates with C4ST-2 to increase the number of CS moieties.
Notably, on the basis of the data in Figure 2 , ChSy-1-ChSy-3 enzyme complexes seemed to play a central role in chondroitin polymerization on α-TM, although every ChSy complex tested polymerized chondroitin on α-TM. In our previous study, ChSy family members coexpressed in various combinations exhibited distinct but overlapping acceptor substrate specificities with two synthetic acceptor substrates, GlcAβ1-3Galβ1-O-naphthalenemethanol and GlcAβ1-3Galβ1-O-C 2 H 4 NH-benzyloxycarbonyl, both of which share a disaccharide sequence with the GAG-protein linkage region tetrasaccharide [4] . When using the two synthetic acceptor substrates, two complexes, ChSy-1-ChPF and ChSy-1-ChSy-3, polymerized more chondroitin than other complexes [4] . Moreover, we recently found that the non-reducing terminal 4-Osulfation of GalNAc residues synthesized by C4ST-1 and ChGn-2 facilitated the elongation of CS chains only when the chondroitin polymerase comprised ChSy-1 and ChPF, and no polymerization was induced on these acceptors when ChSy-1 and ChSy-2, ChSy-1 and ChSy-3, ChSy-2 and ChSy-3, ChSy-2 and ChPF, or ChSy-3 and ChPF were co-expressed [26] . Furthermore, as shown in the present study, the non-reducing terminal GalNAc(4-O-sulfate)-linkage structure of CS was associated with an increase in the number of CS chains when any one of six ChSy complexes was the polymerase (Figure 2) . Thus each ChSy complex may play a specific role in the biosynthesis of CS.
In the present study we propose that the chondroitin backbone was synthesized via two pathways (Figure 7 ). Pathway A shows that after synthesis of the linkage-region tetrasaccharide, the ChSy-1-ChSy-3 complex is primarily responsible for chondroitin polymerization. Pathway B shows that following complete synthesis of the linkage-region tetrasaccharide, ChGn-1 catalyses the transfer of a single GalNAc residue to the tetrasaccharidelinkage region and C4ST-2 then mediates the 4-O-sulfation of the non-reducing terminal GalNAc residue. Finally, the non-reducing terminal 4-O-sulfation of the GalNAc-linkage structure facilitated the elongation of CS chains via chondroitin polymerases that comprised any combination of two ChSy family members, although the chain lengths of chondroitin synthesized by different ChSy enzyme complexes differed (Figure 2 ). These results indicated that the mechanism of CS chain initiation, which is largely mediated by the ChGn-1 and C4ST-2, were similar to, but distinct from, the mechanisms of chain elongation, which was largely mediated by ChGn-2 and C4ST-1 [26] .
In a previous study, it was shown that the synthesis of abnormally long CS chains that occurs during the development of atherosclerosis is accompanied by increases in expression of C4ST-1 and ChGn-2 [28] . In contrast, C4ST-2 and ChGn-1 expression levels do not change during the progression of atherosclerosis, suggesting that C4ST-2 and ChGn-1 may not be involved in CS chain elongation during the development of atherosclerosis [28] . These results indicate that functions of ChGn-1 and ChGn-2, or C4ST-1 and C4ST-2, are different, despite their overlapping substrate specificities in vitro. In addition, the C4ST-1-ChGn-2 and C4ST-2-ChGn-1 complexes are important in the regulation of CS chain length and the number of CS chains respectively. An analysis of ChGn-2-or C4ST-2-knockout mice should provide further insight into the distinct functions of these proteins. C4ST-2-knockout mice may exhibit a similar phenotype to ChGn-1-knockout mice.
ChGn-1-knockout mice had less cartilage than wild-type mice. Sato et al. [29] also indicated that ChGn-1-deficient mice exhibited slight dwarfism due to a minor impairment of endochondral ossification. These results suggest that ChGn-1 is required for normal cartilage development. To date, many of these cartilage deficiencies are characteristic of the degenerative alterations observed with OA (osteoarthritis). OA is a degenerative disease characterized by a loss of matrix CS and cartilage integrity [30] . A genome-wide gene expression analysis that compared human OA cartilage with normal donor cartilage identified an altered level of C4ST-1 expression in OA cartilage [31] . In fact, C4ST-1-knockout mice have severe cartilage defects, and are characterized by disorganized and hypercellular cartilage growth plates with a fibrillated ECM (extracellular matrix) and an overall loss of CS [32] . On the basis of the findings that both C4ST-1 and ChGn-1 play key roles in mammalian chondrocyte development and in the maintenance of healthy cartilage, it is likely that abnormal ChGn-1 and C4ST-2 expression may be involved in the pathogenic mechanisms of OA.
More recently, we found two missense mutations in the ChGn-1 gene, and both were associated with a profound decrease in enzyme activity in two patients with neuropathy [33] . As we found in the present study, ChGn-1 regulated the chain number and amount of CS in these patients, which indicates that patients with neuropathies may suffer from decreased levels of CS. In addition, we demonstrated that ChGn-1 co-operates with C4ST-2 to increase the number of CS moieties. Thus C4ST-2 may also be associated with the pathogenesis of peripheral neuropathies because C4ST-2 abnormalities may inhibit recovery from minor trauma. Studies on larger numbers of patients and complete family studies are in progress.
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